Biohaven Pharma (BHVN) Misses Q4 EPS by 11c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
• JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight